GlassScriptPhysician profile
Miranda L Cebula
NPI 1649646605
$521.61
in general payments reported to CMS, 2019-2025
15 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2023: $20.73 · 2024: $169 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $137.75 | 2024-2025 | Veozah |
| Abbvie INC. | $114.73 | 2021-2024 | |
| Novo Nordisk INC | $47.24 | 2024 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $44.06 | 2021-2025 | Eliquis |
| Medicure Pharma INC. | $24.35 | 2021 | |
| Sanofi Pasteur INC. | $22.77 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.68 | 2025 | Caplyta |
| Organon LLC | $18.39 | 2024 | |
| Lilly USA, LLC | $15.41 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $14.27 | 2021 | |
| Amarin Pharma, INC. | $12.67 | 2021 | |
| Amgen INC. | $12.46 | 2021 | |
| Glaxosmithkline, LLC. | $12.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.02 | 2021 | |
| Axsome Therapeutics, INC. | $11.60 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Cebula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.